HomeAI · summaries
Storia in 3 fonti
Gilead pledges 400K AmBisome doses to fight visceral leishmaniasis in expanded WHO collab
Gilead Sciences and the World Health Organization (WHO) are doubling down on a pact to eliminate deadly parasitic disea | Gilead’s five-year contract with the WHO is centered on providing AmBisome to countries that make up 74% of the global visceral leishmaniasis burden, according to the company.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
- ·
fiercepharma.com
Gilead pledges 400K AmBisome doses to fight visceral leishmaniasis in expanded WHO collab
Gilead Sciences and the World Health Organization (WHO) are doubling down on a pact to eliminate deadly parasitic disea | Gilead’s five-year contract with the WHO is centered on…
- ·
pharmaceutical-technology.com
Gilead teams up with WHO again to eliminate parasitic tropical disease - Pharmaceutical Technology
Gilead will donate vials of its antifungal medication AmBisome to help global efforts in eliminating visceral leishmaniasis.